NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
0 |
-0.74 |
N/A |
N/A |
2024-03-29 |
2023-12 |
-0.7 |
N/A |
N/A |
N/A |
2024-03-29 |
2023-12 |
-0.7 |
-0.5 |
0.2 |
28.57% |
2023-11-13 |
2023-09 |
-1.1 |
N/A |
N/A |
N/A |
2023-11-13 |
2023-09 |
-1.1 |
-0.7 |
0.4 |
36.36% |
2023-08-14 |
2023-06 |
-1.4 |
-1.2 |
0.2 |
14.29% |
Date |
Firm |
Action |
From |
To |
2023-05-24 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-02-01 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-11-08 |
Ascendiant Capital |
Upgrade |
|
Buy |
2022-06-29 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-09-14 |
BESTHOF ROBERT |
Officer |
23.71K |
Sale |
2021-09-01 |
DAIGNEAULT ALESSANDRA |
General Counsel |
31.58K |
Conversion of Exercise of derivative security |
2022-11-27 |
FLYNN PATRICK JOHN |
Director |
0.00 |
Purchase |
2023-08-29 |
GOROVITZ AARON |
Director |
0.00 |
Purchase |
2023-08-29 |
HURVITZ CHAIM |
Director |
2.21M |
Purchase |
2022-11-29 |
JAVITT DANIEL C |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Armistice Capital, LLC |
5.64M |
2.73M |
6.90% |
2023-06-29 |
Vanguard Group Inc |
1.48M |
714.69K |
1.81% |
2023-06-29 |
Sabby Management, LLC |
699.73K |
338.32K |
0.86% |
2023-06-29 |
CVI Holdings, LLC |
483.57K |
233.81K |
0.59% |
2023-06-29 |
Geode Capital Management, LLC |
378.67K |
183.09K |
0.46% |
2023-06-29 |
Blackrock Inc. |
290.71K |
140.56K |
0.36% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
978.92K |
473.31K |
1.20% |
2023-06-29 |
Vanguard Extended Market Index Fund |
448.67K |
216.93K |
0.55% |
2023-05-30 |
Fidelity Extended Market Index Fund |
226.11K |
158.27K |
0.28% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
160.70K |
77.70K |
0.20% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
52.89K |
37.02K |
0.06% |
2023-05-30 |
Fidelity Total Market Index Fund |
44.57K |
31.20K |
0.05% |
Split |
Date |
1 : 10 |
2024-04-02 |